论文部分内容阅读
目的:探讨β受体阻滞剂对高血压合并心房颤动(房颤)患者血清IL-17表达水平的影响。方法:以高血压合并房颤的95例为房颤组,高血压窦性心律的55例为窦性心律组,按接受β阻滞剂治疗与否分成房颤非治疗组43例、房颤治疗组52例、窦性心律非治疗组29例、窦性心律治疗组26例。比较各组血清IL-17表达水平差异。结果:与窦性心律非治疗组相比,房颤非治疗组血清IL-17水平明显升高(P<0.05);而血清IL-17表达在窦性心律组内差异无统计学意义(P>0.05);房颤治疗组血清IL-17水平明显低于其非治疗组(P<0.05)。结论:升高的血清IL-17与高血压合并房颤相关,而β受体阻滞剂治疗降低其血清IL-17表达水平。
Objective: To investigate the effect of β-blocker on serum IL-17 expression in patients with hypertension and atrial fibrillation (AF). Methods: A total of 95 patients with atrial fibrillation (AF) were enrolled in this study. Fifty-five patients with sinus rhythm of essential hypertension were sinus rhythm group. Forty-three patients with atrial fibrillation 52 cases in the treatment group, 29 cases in sinus rhythm non-treatment group and 26 cases in sinus rhythm treatment group. The differences of serum IL-17 expression levels in each group were compared. Results: Compared with sinus rhythm non-treatment group, the level of serum IL-17 in atrial fibrillation non-treatment group was significantly increased (P <0.05), while there was no significant difference in serum IL-17 expression in sinus rhythm group (P > 0.05). The level of serum IL-17 in atrial fibrillation group was significantly lower than that in non-treatment group (P <0.05). CONCLUSION: Elevated serum IL-17 is associated with hypertension with atrial fibrillation, whereas beta-blocker treatment decreases serum IL-17 expression.